IL13Rα2 Promotes Proliferation and Outgrowth of Breast Cancer Brain Metastases.
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 11 2021
15 11 2021
Historique:
received:
01
02
2021
revised:
05
08
2021
accepted:
16
09
2021
pubmed:
22
9
2021
medline:
8
4
2022
entrez:
21
9
2021
Statut:
ppublish
Résumé
The survival of women with brain metastases (BM) from breast cancer remains very poor, with over 80% dying within a year of their diagnosis. Here, we define the function of IL13Rα2 in outgrowth of breast cancer brain metastases (BCBM) We performed IHC staining of IL13Rα2 in BCBM to define its prognostic value. Using inducible shRNAs in TNBC and HER2 High IL13Rα2 expression in BCBM predicted worse survival after BM diagnoses. IL13Rα2 was essential for cancer-cell survival, promoting proliferation while repressing invasion. IL13Rα2 KD resulted in FAK downregulation, repression of cell cycle and proliferation mediators, and upregulation of Ephrin B1 signaling. Ephrin-B1 (i) promoted invasion of BC cells Non-genomic phenotypic adaptations at metastatic sites are critical to BM progression and patients' prognosis. This study opens the road to use IL13Rα2 targeting as a therapeutic strategy for BM.
Identifiants
pubmed: 34544797
pii: 1078-0432.CCR-21-0361
doi: 10.1158/1078-0432.CCR-21-0361
pmc: PMC8595859
mid: NIHMS1742886
doi:
Substances chimiques
IL13RA2 protein, human
0
Interleukin-13 Receptor alpha2 Subunit
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
6209-6221Subventions
Organisme : NCI NIH HHS
ID : P30 CA046934
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA205044
Pays : United States
Organisme : NCI NIH HHS
ID : R37 CA227984
Pays : United States
Organisme : NIH HHS
ID : S10 OD027023
Pays : United States
Informations de copyright
©2021 The Authors; Published by the American Association for Cancer Research.
Références
Cancer Metastasis Rev. 2012 Jun;31(1-2):353-73
pubmed: 22549394
Nat Med. 2010 Jan;16(1):116-22
pubmed: 20023634
J Biol Chem. 2012 Aug 31;287(36):30215-27
pubmed: 22778273
Ann Surg Oncol. 2017 Nov;24(12):3780-3787
pubmed: 28634667
Nature. 2006 May 25;441(7092):444-50
pubmed: 16724056
Breast Cancer Res. 2015 Jul 25;17:98
pubmed: 26208975
J Natl Cancer Inst. 2008 Aug 6;100(15):1092-103
pubmed: 18664652
Front Oncol. 2019 Feb 05;9:32
pubmed: 30805303
Cold Spring Harb Protoc. 2013 Jul 01;2013(7):631-5
pubmed: 23818675
Nat Rev Cancer. 2010 Mar;10(3):165-80
pubmed: 20179713
Cancer Res. 2012 Jun 1;72(11):2780-90
pubmed: 22505647
Structure. 2010 Mar 10;18(3):332-42
pubmed: 20223216
Mol Cancer Ther. 2006 Dec;5(12):3162-9
pubmed: 17172420
J Cell Biol. 1998 Dec 28;143(7):1997-2008
pubmed: 9864370
Nature. 2009 Jun 18;459(7249):1005-9
pubmed: 19421193
Cell. 2014 Feb 27;156(5):1002-16
pubmed: 24581498
Am J Pathol. 2010 Jun;176(6):2958-71
pubmed: 20382702
J Exp Med. 2001 Dec 17;194(12):1743-54
pubmed: 11748276
Cancer Res. 2004 Dec 15;64(24):9160-6
pubmed: 15604287
N Engl J Med. 2016 Dec 29;375(26):2561-9
pubmed: 28029927
Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):984-9
pubmed: 24395782
Elife. 2016 Jul 29;5:
pubmed: 27472901
J Exp Med. 2003 Mar 17;197(6):703-9
pubmed: 12642602
Nat Biotechnol. 2013 Jan;31(1):46-53
pubmed: 23222703
Clin Cancer Res. 2008 Jan 1;14(1):199-208
pubmed: 18172271
Nat Biotechnol. 2010 May;28(5):511-5
pubmed: 20436464
BMC Cancer. 2018 Jan 30;18(1):103
pubmed: 29378533
Nat Med. 2006 Jan;12(1):99-106
pubmed: 16327802
Biomed Res Int. 2014;2014:952128
pubmed: 25247196
Oncogene. 2019 Jun;38(24):4685-4699
pubmed: 30796353
Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):20021-6
pubmed: 21030678
Nat Rev Mol Cell Biol. 2016 Apr;17(4):240-56
pubmed: 26790531
Genome Biol. 2014;15(12):550
pubmed: 25516281
Mol Cancer Res. 2021 Apr;19(4):688-701
pubmed: 33443114
Annu Rev Pharmacol Toxicol. 2015;55:465-87
pubmed: 25292427
Breast Dis. 2006-2007;26:139-47
pubmed: 17473372
Mol Med. 2000 May;6(5):440-9
pubmed: 10952023
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Mucosal Immunol. 2019 Sep;12(5):1174-1186
pubmed: 31308480
Nat Cell Biol. 2000 Feb;2(2):62-9
pubmed: 10655584
J Clin Oncol. 2011 Jan 20;29(3):330-6
pubmed: 21149657
Nat Methods. 2015 Apr;12(4):357-60
pubmed: 25751142
Breast J. 2012 Jul-Aug;18(4):345-50
pubmed: 22607041
Breast Cancer Res Treat. 2008 Oct;111(3):523-30
pubmed: 17990100
Cancer Res. 2015 Jun 15;75(12):2434-44
pubmed: 25896327
Cancer Res. 2020 Jan 15;80(2):163-169
pubmed: 31704888
J Natl Cancer Inst. 2019 Apr 1;111(4):388-398
pubmed: 29961873
Mol Cell Proteomics. 2015 Sep;14(9):2316-30
pubmed: 26041846
Cancer Res. 2000 Mar 1;60(5):1168-72
pubmed: 10728667
Cancer Microenviron. 2012 Apr;5(1):19-28
pubmed: 21892699
Biochem Biophys Res Commun. 2019 Apr 9;511(3):536-543
pubmed: 30824191
Clin Cancer Res. 1995 Nov;1(11):1253-8
pubmed: 9815919
Nat Methods. 2014 Oct;11(10):982-4
pubmed: 25264773
Nat Med. 2018 Jul;24(7):1024-1035
pubmed: 29892069
Oncogene. 2016 Jun 2;35(22):2881-92
pubmed: 26411365
Cell Rep. 2013 Aug 29;4(4):830-41
pubmed: 23972995
Methods Enzymol. 2014;536:165-72
pubmed: 24423275
Nat Commun. 2017 Dec 4;8(1):1913
pubmed: 29203859